The report will be delivered in 2-3 business days.

Multiple Sclerosis Drugs Market Global Report 2020

Starting Price : $ 4000.00 | Pages : 200 | Published : April 2020 | SKU CODE : 7608 | Format :


The multiple sclerosis drugs market consists of sale of multiple sclerosis drugs and related services. Multiple sclerosis (MS) is an autoimmune disease where the immune system attacks the protective fat layer called myelin, around the nerve fibers and causes problems with muscle control, vision and other body functions. It is a disease that affects brain, spinal cord and the optic nerves resulting in loss of balance, coordination and compromised vision. The disease can result in long term disability.

The global multiple sclerosis drugs market was worth $20.83 billion in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 5.20% and reach $25.52 billion by 2023.

The multiple sclerosis drugs market has been geographically segmented into North America, Western Europe, Asia-Pacific, Eastern Europe, South America and Middle East & Africa. North America is expected to be the largest region in the forecast period.

The multiple sclerosis drugs market covered in this report is segmented by drug class into immunomodulators, immunosuppressants, interferons, others. It is also segmented by distribution channels into hospital pharmacy, retail pharmacy, and online stores and by route of administration: oral drugs and, parenteral drugs.

The growth of multiple sclerosis drugs market is aided by the support from government as well as non-government organization. The government and non-government organizations fund several schemes and programs to offer their support to enhance the quality of life of people affected with multiple sclerosis (MS). For instance, in 2019, the government of Alberta in partnership with the department of Economic Development, Trade and Tourism in Canada invested $1million towards the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo) to support the research and innovations to enhance understanding and treatment for MS disease. CanProCo is an initiative to consolidate the efforts of nearly 50 MS researchers from various disciplines across Canada.  The initiative was further funded by the Canada Brain Research, Biogen Canada and the MS Society of Canada, as well as Hoffmann-La Roche Limited (Roche Canada) to raise a total of $10 million. Appropriate financial support from the government and non-government organizations boosts the growth of multiple sclerosis drugs market.

The high cost of drugs to treat multiple sclerosis (MS) restricts the growth of multiple sclerosis drugs market. The MS is a cureless disease with high chances of disability and requires lifelong treatment. Despite the heavy competition among the drug companies, the cost of MS drugs is high, increasing the overall cost of treatment. The companies operating in the multiple sclerosis drugs market often have to work towards reducing the cost of these drugs to justify its cost-effectiveness to its consumers. As reported by Institute for Clinical and Economic Review (ICER) in 2017, the MS drugs costs roughly between $63,000 and $104,000 annually. For instance, in 2019, after receiving criticism by National Multiple Sclerosis Society on the high price of Vumerity, a drug to treat relapse MS, Biogen and Alkermes had to reduce the prices of the drug to $88,000 per year in order to make it affordable to the patients. The high cost of drugs, which are required lifelong negatively affects the growth of the multiple sclerosis drugs market.

The companies are rapidly intensifying their efforts to focus on new product launches to cater to the rising demands for MS drugs. The multiple sclerosis requires a lifelong treatment, which increases the overall cost of treating a patient. In order to provide better and effective treatment companies in the multiple sclerosis market are developing drugs specific to the treatment of multiple sclerosis. Following the trend, in 2019, FDA approved Novartis’ Mayzent (siponimod) and EMD Serono’s Mavenclad (cladribrine) for the treatment of relapsing remitting multiple sclerosis (RRMS), and active secondary progressive multiple sclerosis (SPMS).  Both the drugs were launched as an easy-to-consume oral drug.

In 2019, Bristol-Myers Squibb, a USA based pharmaceutical company, acquired Celgene for $74billion. Through the acquisition Bristol-Myers Squibb aims to increase its product portfolio by utilizing the existing products of Celgene along with its technical and pipeline support. Ozanimod is one of the Celgene’s pipelined drugs for the treatment of relapsing multiple sclerosis. The drug is currently in phase III clinical trials to be approved by FDA. Celgene is a USA based producer and marketer of medicines for cancer and inflammatory disorders such as multiple sclerosis.

The major players in the global multiple sclerosis drugs market are Biogen, Novartis, Roche, Bayer HealthCare, Pfizer, Inc., Merck & Co., Inc., Sanofi, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline, Acorda Therapeutics Inc., Actelion Pharmaceuticals (Johnson & Johnson), EMD Serono (Merck KGaA), AbbVie, Inc.,  Betaseron, CinnoVex, Extavia, Rebif, Tysabr

The countries covered in the global multiple sclerosis drugs market report are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia

The Global Multiple Sclerosis Drugs Market is segmented: 1) By Drug Class: Immunomodulators, Immunosuppressants, Interferons, Others 2) By Distribution Channels: Hospital Pharmacy, Retail Pharmacy, Online Stores 3) By Route Of Administration: Oral Drugs, Parenteral Drugs

    1. Executive Summary

    2. Multiple Sclerosis Drugs Market Characteristics

    3. Multiple Sclerosis Drugs Market Size And Growth

    3.1. Global Multiple Sclerosis Drugs Historic Market, 2015 - 2019, $ Billion

    3.1.1. Drivers Of The Market

    3.1.2. Restraints On The Market

    3.2. Global Multiple Sclerosis Drugs Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion

    3.2.1. Drivers Of The Market

    3.2.2. Restraints On the Market

    4. Multiple Sclerosis Drugs Market Segmentation

    4.1. Global Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    Immunomodulators

    Immunosuppressants

    Interferons

    Others

    4.2. Global Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    Hospital Pharmacy

    Retail Pharmacy

    Online Stores

    4.3. Global Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    Oral drugs

    Parenteral drugs

    5. Multiple Sclerosis Drugs Market Regional And Country Analysis

    5.1. Global Multiple Sclerosis Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    5.2. Global Multiple Sclerosis Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    6. Asia-Pacific Multiple Sclerosis Drugs Market  

    6.1. Asia-Pacific Multiple Sclerosis Drugs Market Overview  

    6.2. Asia-Pacific Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    6.3. Asia-Pacific Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    7. China Multiple Sclerosis Drugs Market  

    7.1. China Multiple Sclerosis Drugs Market Overview  

    7.2. China Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

    7.3. China Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

    8. India Multiple Sclerosis Drugs Market  

    8.1. India Multiple Sclerosis Drugs Market Overview  

    8.2. India Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    8.3. India Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    9. Japan Multiple Sclerosis Drugs Market  

    9.1. Japan Multiple Sclerosis Drugs Market Overview  

    9.2. Japan Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    9.3. Japan Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    10. Australia Multiple Sclerosis Drugs Market  

    10.1. Australia Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    10.2. Australia Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    11. Indonesia Multiple Sclerosis Drugs Market  

    11.1. Indonesia Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    11.2. Indonesia Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    12. South Korea Multiple Sclerosis Drugs Market  

    12.1. South Korea Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    12.2. South Korea Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    13. Western Europe Multiple Sclerosis Drugs Market  

    13.1. Western Europe Multiple Sclerosis Drugs Market Overview

    13.2. Western Europe Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    13.3. Western Europe Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    14. UK Multiple Sclerosis Drugs Market  

    14.1. UK Multiple Sclerosis Drugs Market Overview

    14.2. UK Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    14.3. UK Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    15. Germany Multiple Sclerosis Drugs Market  

    15.1. Germany Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    15.2. Germany Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    16. France Multiple Sclerosis Drugs Market  

    16.4. France Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    16.5. France Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    17. Eastern Europe Multiple Sclerosis Drugs Market  

    17.1. Eastern Europe Multiple Sclerosis Drugs Market Overview

    17.2. Eastern Europe Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    17.3. Eastern Europe Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    18. Russia Multiple Sclerosis Drugs Market  

    18.1. Russia Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    18.2. Russia Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    19. North America Multiple Sclerosis Drugs Market  

    19.1. North America Multiple Sclerosis Drugs Market Overview

    19.2. North America Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    19.3. North America Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    20. USA Multiple Sclerosis Drugs Market  

    20.1. USA Multiple Sclerosis Drugs Market Overview

    20.2. USA Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    20.3. USA Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    21. South America Multiple Sclerosis Drugs Market  

    21.1. South America Multiple Sclerosis Drugs Market Overview

    21.2. South America Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    21.3. South America Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    22. Brazil Multiple Sclerosis Drugs Market  

    22.1. Brazil Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    22.2. Brazil Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    23. Middle East Multiple Sclerosis Drugs Market  

    23.1. Middle East Multiple Sclerosis Drugs Market Overview

    23.2. Middle East Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    23.3. Middle East Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    24. Africa Multiple Sclerosis Drugs Market  

    24.1. Africa Multiple Sclerosis Drugs Market Overview

    24.2. Africa Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    24.3. Africa Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

    25. Multiple Sclerosis Drugs Market Competitive Landscape And Company Profiles

    25.1. Multiple Sclerosis Drugs Market Competitive Landscape

    25.2. Multiple Sclerosis Drugs Market Company Profiles

    25.2.1. Biogen

    25.2.1.1. Overview

    25.2.1.2. Products and Services

    25.2.1.3. Strategy

    25.2.1.4. Financial Performance

    25.2.2. Novartis

    25.2.2.1. Overview

    25.2.2.2. Products and Services

    25.2.2.3. Strategy

    25.2.2.4. Financial Performance

    25.2.3. Roche

    25.2.3.1. Overview

    25.2.3.2. Products and Services

    25.2.3.3. Strategy

    25.2.3.4. Financial Performance

    25.2.4. Bayer HealthCare

    25.2.4.1. Overview

    25.2.4.2. Products and Services

    25.2.4.3. Strategy

    25.2.4.4. Financial Performance

    25.2.5. Pfizer, Inc.

    25.2.5.1. Overview

    25.2.5.2. Products and Services

    25.2.5.3. Strategy

    25.2.5.4. Financial Performance

    26. Key Mergers And Acquisitions In The Multiple Sclerosis Drugs Market

    27. Multiple Sclerosis Drugs Market Trends And Strategies

    28. Multiple Sclerosis Drugs Market Future Outlook and Potential Analysis

    29. Appendix

    29.1. Abbreviations

    29.2. Currencies

    29.3. Research Inquiries

    29.4. The Business Research Company

    29.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2015-2019, $ Billion
  • Table 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 3: Global Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 4: Global Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 5: Global Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 6: Global Multiple Sclerosis Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 7: Global Multiple Sclerosis Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 8: Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 9: Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 10: China, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 11: China, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 12: India, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 13: India, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 14: Japan, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 15: Japan, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 16: Australia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 17: Australia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 18: Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 19: Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 20: South Korea, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 21: South Korea, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 22: Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 23: Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 24: UK, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 25: UK, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 26: Germany, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 27: Germany, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 28: France, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 29: France, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 30: Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 31: Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 32: Russia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 33: Russia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 34: North America, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 35: North America, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 36: USA, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 37: USA, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 38: South America, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 39: South America, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 40: Brazil, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 41: Brazil, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 42: Middle East, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 43: Middle East, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 44: Africa, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 45: Africa, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 46: Biogen Financial Performance
  • Table 47: Novartis Financial Performance
  • Table 48: Roche Financial Performance
  • Table 49: Bayer HealthCare Financial Performance
  • Table 50: Pfizer, Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2015-2019, $ Billion
  • Figure 2: Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 3: Global Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 4: Global Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 5: Global Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 6: Global Multiple Sclerosis Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 7: Global Multiple Sclerosis Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 8: Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 9: Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 10: China, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 11: China, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 12: India, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 13: India, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 14: Japan, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 15: Japan, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 16: Australia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 17: Australia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 18: Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 19: Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 20: South Korea, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 21: South Korea, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 22: Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 23: Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 24: UK, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 25: UK, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 26: Germany, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 27: Germany, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 28: France, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 29: France, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 30: Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 31: Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 32: Russia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 33: Russia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 34: North America, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 35: North America, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 36: USA, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 37: USA, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 38: South America, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 39: South America, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 40: Brazil, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 41: Brazil, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 42: Middle East, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 43: Middle East, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 44: Africa, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 45: Africa, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 46: Biogen Financial Performance
  • Figure 47: Novartis Financial Performance
  • Figure 48: Roche Financial Performance
  • Figure 49: Bayer HealthCare Financial Performance
  • Figure 50: Pfizer, Inc. Financial Performance
New Drug Innovations In The Pharmaceuticals Market
Antithrombotic Drugs Are Being Used To Prevent Various Disorders
Increasing Rate Of The Elder Population Is Driving The Ophthalmology Drugs Market
Innovations In The Diabetes Therapies Market
Allergan plc- One Of The Largest Companies In The Global Drugs For Benign Prostatic Hypertrophy Market
Innovation And Development Of Combination Drugs To Enhance Growth Of The Ovarian Cancer Drugs Market
The Global Prostate Cancer Drugs Market Will Reach Around $10 By 2022
Antivirals Are The Largest And Fastest Growing Segment Of The Anti-Infective Drugs Market
Ophthalmology Drugs Market By Type (Antglaucoma Drugs, Dry Eye Medication And Other Ophthalmological Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores And Others), By Drug Classification (Branded Drugs And Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Personal Care Services Market Report - By Type (Beauty Salons, Spas & Massage, Diet And Weight Reducing Centers, Other Personal Care Services), By End User Location (On Premise, Off Premise), By Age ( Below 15, 15-40, 40-65, Above 65), By Gender (Female, Male) And By Regions | Global Market Opportunities And Strategies To 2030
View Report
Dry Eye Medication Market By Type (Aqueous Dry Eye Syndrome, Evaporative Dry Eye Syndrome), By End-User (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies), By Product Type (Liquid Drops, Gel, Liquid Wipes, Eye Ointment) And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Coronavirus (COVID-19) Current Therapy Market Global Report 2020: COVID 19 Growth And Change
View Report
COVID19 Drug Associated APIs Market Global Report 2020: COVID 19 Growth And Change
View Report
COVID19 Vaccine & Therapeutics Clinical Trial Analysis 2020
View Report
COVID19 Vaccine And Therapeutics Pipeline Analysis 2020
View Report
Remdesivir Market Global Report 2020-30: COVID 19 Growth and Change
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)